A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer.

Furrer, Marc A.; Papa, Nathan; Luetolf, Sandro; Roth, Beat; Cumberbatch, Marcus; Dorin Vartolomei, Mihai; Thomas, Benjamin C.; Thoeny, Harriet C.; Seiler, Roland; Thalmann, George N.; Kiss, Bernhard (2022). A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer. BJU international, 130(3), pp. 306-313. Wiley 10.1111/bju.15579

Text Tha_A_longitudinal_study_evaluating_interim_assessment_ofneoadjuvant_chemotherapy_for_bladder_cancer.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (642kB) | Request a copy

OBJECTIVES

To evaluate the usefulness of radiological re-staging after two and four cycles of neoadjuvant chemotherapy (NAC), the impact of re-staging on further patient management, and the correlation between clinical and final pathological tumour stage at radical cystectomy (RC).

PATIENTS AND METHODS

We conducted a longitudinal, single-centre, cohort study of prospectively collected consecutive patients who underwent NAC and RC for urothelial muscle-invasive bladder cancer between July 2001 and December 2017. Patients underwent repeated computed tomography scans for re-staging after two cycles of NAC and after completion of NAC before RC.

RESULTS

Of 180 patients, 110 had ≥four cycles of NAC and had complete imaging available. In the entire cohort, further patient management was only changed in 2/180 patients (1.1%) after two cycles of NAC based on radiological findings. Patients who were stable after two cycles but then downstaged after at least four cycles of NAC had a similarly lowered risk of death (hazard ratio [HR] 0.53). Only one patient downstaged after two cycles was subsequently upstaged after four cycles. Clinical downstaging was observed in 51 patients (46%), 55 patients (50%) had no change in clinical stage and four patients (3.6%) were clinically upstaged. Patients clinically downstaged after four cycles of NAC had a lower risk of death (HR 0.49, 95% confidence interval 0.25-0.94; P = 0.033) compared to those with no change or upstaged after completion of NAC.

CONCLUSIONS

Re-staging of muscle-invasive bladder cancer after two cycles of NAC offers little additional information, rarely changes patient management, and may therefore be omitted, whereas re-staging after completion of NAC by CT is a strong predictor of overall survival.

Interest & Impact

Downloads

2 since deposited on 13 Oct 2021
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item